Argenx announced that the U.S. FDA has approved VYVGART Hytrulo for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy. VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection. It is the first and only neonatal Fc receptor blocker approved for the treatment of CIDP.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Unveils ‘Vision 2030’ for Transforming Autoimmunity
- argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
- argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
- Argenx price target raised to EUR 375 from EUR 360 at Barclays
- Argenx price target lowered to $510 from $515 at Morgan Stanley